Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate.
Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by 2021, subject to FDA approval.
Get the full story at our sister site, Drug Delivery Business News.
Tell Us What You Think!